- ►shouxi.net IB Hirsch - The New England journal of medicine, 2005 - nejm.highwire.org By the early 1980s, the development of purified pork insulin and then recombinant human insulin
virtually eliminated insulin allergy and immune-mediated lipoatrophy. These achievements marked a
slowdown in the innovation of ... Cited by 337 - Related articles - All 6 versions
- ►pr-ide.be [PDF] K Hermansen, P Fontaine, KK Kukolja, V Peterkova, G … - Diabetologia, 2004 - Springer Aims/hypothesis. The aim of the trial was to compare the efficacy and tolerability of two types of
basal-bolus therapy, using either the soluble long-acting basal insu- lin analogue, insulin detemir,
in combination with the ... Cited by 231 - Related articles - BL Direct - All 10 versions
K Hermansen, M Davies, T Derezinski, G Martinez … - Diabetes Care, 2006 - Am Diabetes Assoc RESULTS—At 24 weeks, A1C had decreased by 1.8 and 1.9% (from 8.6 to 6.8 and from 8.5 to 6.6%) for
detemir and NPH, respectively (NS). In both groups, 70% of participants achieved an A1C ≤7.0%, but
the proportion achieving this ... Cited by 225 - Related articles - BL Direct - All 9 versions
T Haak, A Tiengo, E Draeger, M Suntum, W … - Diabetes Obesity and …, 2005 - fe-inzichten.nl Aim: The aim of this study was to compare the efficacy and safety of a basal-bolus insulin regimen
comprising either insulin detemir or neural protamine hagedorn (NPH) insulin in combination with
mealtime insulin aspart in patients ... Cited by 193 - Related articles - View as HTML - All 5 versions
K Rašlová, M Bogoev, I Raz, G Leth, MA Gall, N … - Diabetes research and …, 2004 - Elsevier This trial compared the efficacy and safety of basal-bolus therapy using either the soluble basal
insulin analogue insulin detemir (IDet) in combination with meal-time rapid-acting analogue insulin
aspart (IAsp), or NPH insulin (NPH) ... Cited by 160 - Related articles - All 8 versions
P Home, P Bartley, D Russell-Jones, H Hanaire- … - Diabetes Care, 2004 - Am Diabetes Assoc RESULTS—With both insulin detemir groups, clinic fasting plasma glucose was lower than with NPH
insulin (IDet 12h vs. NPH, −1.5 mmol/l [95% CI −2.51 to −0.48], P = 0.004; IDet morn+bed vs.
NPH, −2.3 mmol/l (−3.32 to ... Cited by 153 - Related articles - BL Direct - All 7 versions
- ►diabetesjournals.org J Plank, M Bodenlenz, F Sinner, C Magnes, E … - Diabetes Care, 2005 - Am Diabetes Assoc RESULTS—Duration of action for insulin detemir was dose dependent and varied from 5.7, to 12.1, to
19.9, to 22.7, to 23.2 h for 0.1, 0.2, 0.4, 0.8, and 1.6 units/kg, respectively. Interpolation of
the dose-response relationships for ... Cited by 129 - Related articles - All 9 versions
- ►publichealth.ru [PDF] D Daneman - The Lancet, 2006 - Elsevier Type 1 diabetes accounts for only about 5–10% of all cases of diabetes; however, its incidence
continues to increase worldwide and it has serious short-term and long-term implications. The
disorder has a strong genetic ... Cited by 126 - Related articles - All 27 versions
D Russell-Jones, R Simpson, B Hylleberg, E Draeger, J … - Clinical therapeutics, 2004 - Elsevier Methods: This was a 6-month, prospective, randomized, open-label, controlled, parallel-group trial
conducted at 92 sites in Europe and Australia. The trial population included men and women with type
1 DM for at least 1 year aged ≥ ... Cited by 122 - Related articles - All 4 versions
S Havelund, A Plum, U Ribel, I Jonassen, A Vølund, … - Pharmaceutical …, 2004 - Springer The peptide hormone, insulin, is produced and stored in pancreatic beta-cells. An adaptation of
beta-cell insulin pro- duction is the assembly of insulin molecules at high concen- tration in the
presence of zinc ions into hexamers ... Cited by 94 - Related articles - BL Direct - All 3 versions
